Inhibikase Therapeutics, Inc. Quarterly Operating Lease, Liability in USD from Q3 2022 to Q3 2024

Taxonomy & unit: us-gaap: USD
Description: Present value of lessee's discounted obligation for lease payments from operating lease.
Summary: Inhibikase Therapeutics, Inc. quarterly Operating Lease, Liability history and growth rate from Q3 2022 to Q3 2024.
Inhibikase Therapeutics, Inc. Operating Lease, Liability for the quarter ending September 30, 2024 was $145K, a 46.2% decline year-over-year.

Operating Lease, Liability, Quarterly (USD)

Operating Lease, Liability, YoY Quarterly Growth (%)

Period	Value	YoY Chg	Change %	Date	Report	Filed
Q3 2024	$145K	-$125K	-46.2%	Sep 30, 2024	10-Q	2024-11-14
Q2 2024	$178K	-$120K	-40.3%	Jun 30, 2024	10-Q	2024-08-14
Q1 2024	$209K	-$116K	-35.5%	Mar 31, 2024	10-Q	2024-05-15
Q4 2023	$240K	-$111K	-31.6%	Dec 31, 2023	10-K	2024-03-27
Q3 2023	$270K	-$104K	-27.8%	Sep 30, 2023	10-Q	2023-11-14
Q2 2023	$298K			Jun 30, 2023	10-Q	2023-08-14
Q1 2023	$325K			Mar 31, 2023	10-Q	2023-05-15
Q4 2022	$351K			Dec 31, 2022	10-K	2023-03-31
Q3 2022	$374K			Sep 30, 2022	10-Q	2022-11-14

* An asterisk sign (*) next to the value indicates that the value is likely invalid.